- Adjusted EPS: Amgen’s adjusted EPS for Q1 reached $4.90, significantly surpassing the estimate of $4.25. This marks a notable increase from the previous year’s $3.96.
- Revenue: The total revenue for Amgen in Q1 stood at $8.15 billion, a 9.4% increase year-over-year, beating the estimate of $8.05 billion.
- Product Sales: Total product sales increased by 11% year-over-year to $7.87 billion, exceeding the estimate of $7.71 billion.
- Outstanding Performers: Products like Repatha, Evenity, and Tezspire showed impressive revenue growth, surpassing their respective estimates.
- Mixed Product Performance: Products such as Enbrel and Amgevita saw a decline, with revenues falling short of estimates.
- Adjusted Operating Income: Increased by 17% year-over-year to $3.60 billion, beating the estimate of $3.33 billion, with an improved operating margin of 45.7%.
- Research & Development: Adjusted R&D expenses climbed by 12% to $1.48 billion, below the estimated $1.57 billion.
- 2025 Guidance: Amgen maintains its forecast for adjusted EPS in the range of $20 to $21.20 and expects revenue between $34.3 billion and $35.7 billion.
- Product Development: Phase 3 trials of their product, MariTide, for obesity continue, with further studies expected in 2025. A phase 1 study of AMG 513 is also currently enrolling patients.
Amgen Inc on Smartkarma
Analysts on Smartkarma, such as Baptista Research, have been actively covering Amgen Inc‘s strategic moves and financial performance. One report titled “Amgen’s Big Bet on Obesity: Is This the Pharma Giant’s Next Breakout Moment?” highlights the company’s focus on the obesity drug market, with its drug MariTide showing promising Phase II results and ongoing Phase III trials targeting diabetic and non-diabetic patients. Analysts foresee Amgen positioning itself in a potential $100 billion market by 2030.
Another report by Baptista Research, “Amgen: How Its $3.5 Billion Acquisition & Its High-Stakes Drug Pipeline Are Reshaping Its Growth Strategy,” emphasizes Amgen’s impressive revenue growth of 19% in 2024, driven by success across therapeutic areas despite challenges like pricing pressures. The report acknowledges the company’s strategic acquisitions and pipeline development as key drivers of its future growth potential.
A look at Amgen Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Amgen Inc., a leading independent biotechnology company, has displayed remarkable strength in its overall outlook as indicated by its Smartkarma Smart Scores. With a solid Dividend score of 4 and an impressive Momentum score of 5, Amgen is showing resilience and growth potential in the long term.
Specializing in developing innovative medicines for serious diseases, Amgen’s strategic focus on human therapeutics based on advancements in cellular and molecular biology sets it apart in the industry. While the Value score may indicate room for improvement, the company’s strong performance in Dividend, Growth, Resilience, and Momentum signifies a promising future for investors seeking stability and growth within the biotechnology sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
